Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

46.62 +2.36 (+5.33%)
Streaming Delayed Price Updated: 3:19 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Earns $10 Million Phase 1 Milestone Payment
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals, inc (ARWR) Q3 2021 Earnings Call Transcript ↗
ARWR earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Recap: Arrowhead Pharmaceuticals Q3 Earnings ↗
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08%... 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals: Buy the Dip? ↗
This biotech underdog offers more than meets the eye. 
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Russell 2000 Traders Place Bearish Bets Via IWM ETF ↗
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM... 
Via Benzinga
News headline image
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright ↗
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: 
Via Benzinga
News headline image
Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer ↗
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell... 
Via Benzinga
News headline image
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher ↗
Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to 4,348.47. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
S&P 500 Logs Another Record High as "Fear Gauge" Dips ↗
Stocks are modestly in the black midday, thanks to upbeat monthly jobs data that showed 850,000 jobs were added in June. 
Via Talk Markets
Topics Stocks
News headline image
56 Biggest Movers From Friday ↗
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 73.2% to close at $18.79. A 13G... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million... 
Via Benzinga
News headline image
Arrowhead Stock Plunges, Alector Stock Surges On Drug News ↗
Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged. 
Via Investor's Business Daily
News headline image
Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet ↗
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to 4,340.12. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today ↗
A paused clinical trial with an important asset wasn't what investors wanted to hear today. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5... 
Via Benzinga
News headline image
Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models ↗
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the... 
Via Benzinga
News headline image
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
News headline image
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.